Transcriptomics Technologies Market Analysis

  • Report ID: 5982
  • Published Date: Sep 16, 2025
  • Report Format: PDF, PPT

Transcriptomics Technologies Market Segmentation:

Technology Segment Analysis

Based on technology, next-generation sequencing segment in the transcriptomics technologies market is anticipated to hold 40% of the revenue share during the forecast period. Higher sensitivity to identify low-frequency variants, quicker turnaround times for large sample volumes, increased throughput with sample multiplexing, and the capacity to sequence hundreds to thousands of genes or gene regions at once are among the advantages provided by next-generation sequencing techniques. Furthermore, the segment's growth is being driven by the rapid advancements in technology that allow for the investigation of the cellular transcriptome from several perspectives, the expansion of NGS's application areas, and the growing outsourcing of sequencing technologies. There is now a significant amount of sequencing data available at a reasonable cost because to recent advancements in next-generation sequencing technologies. Studies on transcriptomics and genomes have been transformed by it. Global total revenues were estimated to be 4.2 billion dollars in 2016, and estimates indicate that by 2025, this figure will rise to around 23 billion dollars.

Application Segment Analysis

Based on application, drug discovery & research segment in the transcriptomics technologies market is anticipated to hold 30% of the revenue share during the forecast period. Segment is anticipated to stay in the lead during the projection period due to a growth in the number of product approvals and a rise in the demand for medication research. Growing private and public funding for research, along with R&D investments by pharmaceutical and biotechnology companies, are anticipated to drive industry growth because of the rigorous genomics and proteomics R&D initiatives and the application of RNA sequencing technologies in analytical research. For instance, the publication states that genome-based detection rates for several Mendelian illnesses will reach a ceiling of roughly 50% in 2021.

Our in-depth analysis of the global transcriptomics technologies market includes the following segments:

          Product Type

  • Analyzers
  • Reagent Kits
  • Software

          Technology

  • Microarrays
  • Gene Regulations Technologies
  • Polymerase Chain Reaction
  • Next-Generation Sequencing

          Application

  • Clinical
  • Diagnostics
  • Toxicogenomic
  • Comparative Transcriptomics Studies
  • Drug Discovery & Research
  • Bioinformatics

          End Use

  •  Academic Research & Government Institutes
  • Hospitals & Diagnostic Centers
  • Pharmaceutical & Biotechnology Companies

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of transcriptomics technologies is estimated at USD 8.62 billion.

The global transcriptomics technologies market size was more than USD 8.01 billion in 2025 and is anticipated to witness a CAGR of more than 8.5%, crossing USD 18.11 billion revenue by 2035.

North America transcriptomics technologies market will hold more than 33% share by 2035, attributed to technological advancements and expanded drug discovery practices.

Key players in the market include Danaher Corporation, Agilent Technologies, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Pacific Bioscience of California, Inc., BioSkryb Genomics, Agilent Technologies Inc., Parse Biosciences.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos